Antonino Musolino - Concepedia

Author

Antonino Musolino

Also Known As

A Musolino, A. Musolino, AMC Musolino, Antonino Musolino, Antonio Musolino, Maria MICHIARA, Musolino, Musolino A, Musolino, Antonino, Ornella Garrone

358

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

University of Parma Istituti di Ricovero e Cura a Carattere Scientifico Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori University of Modena and Reggio Emilia Istituto Oncologico Veneto

About

Antonino Musolino is an author at University of Parma specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	785
2	Health Sciences	3	3	88
3	Public Health	2	2	49
4	Engineering	1	1	17
5	Nursing	1	1	72

Antonino Musolino

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer Antonino Musolino, Nadia Naldi, Beatrice Bortesi, Journal of Clinical Oncology	2008	949
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, Journal of Clinical Oncology	2012	366
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, JAMA Oncology	2021	336
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer Nicholas C. Turner, Seock‐Ah Im, Cristina Saura, New England Journal of Medicine	2024	178
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study Pierfranco Conté, Antonio Frassoldati, Giancarlo Bisagni, Annals of Oncology	2018	152
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer Antonino Musolino, Laura Ciccolallo, Michele Panebianco, Cancer	2010	135
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study Antonino Musolino, Maria Angela Bella, Beatrice Bortesi, The Breast Breast OncologySomatic VariantMolecular MarkersEarly-onset Breast CancerMedicine	2007	130
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, The Oncologist	2015	109
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy Antonino Musolino, Mario Campone, Patrick Neven, Breast Cancer Research	2017	105
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer Maria Vittoria Dieci, Pierfranco Conté, Giancarlo Bisagni, Annals of Oncology	2019	94

Page 1